Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 21Melanoma 20Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 9Pancreatic Neoplasms 8Colorectal Neoplasms 8Rectal Neoplasms 4Triple Negative Breast Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Colonic Neoplasms 3Thyroid Neoplasms 2Meningioma 2Leukemia, Myeloid, Acute 2Glioma 2Breast Neoplasms 2Brain Neoplasms 2Advanced Solid Tumors 2Adenocarcinoma of Lung 2Thyroid Carcinoma, Anaplastic 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors, KRAS Mutation; SOS1 1Solid Tumors 1Solid Tumor Cancer 1Solid Tumor 1Sarcoma 1Rhabdoid Tumor 1Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer 1Recurrence 1

Interventions

trametinib 1ribociclib 1nazartinib 1naporafenib 1capmatinib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × EGFR-mutant Non-small Cell Lung Cancer × trametinib × Clear all
NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Novartis

Phase 1 Active not recruiting
105 enrolled
Thoracic

EGFR-mutant Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡